《神經(jīng)性疼痛藥物治療指南》內(nèi)容預(yù)覽 

    NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales. This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering. 

    Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.

    This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

    In this guideline, most of the information about the evidence is included in chapter 2. Details of which pharmacological treatments (table 2) and neuropathic pain conditions (table 3) were considered, as well as a summary of the characteristics of all included studies (table 5), are given in section 2.1. The evidence statements (section 2.2) are the overall desc**tive summary of the evidence. Each evidence statement is linked to an evidence review, which is presented as a GRADE profile (section 2.3). Each GRADE profile includes the characteristics of the evidence, the detailed results for the primary outcomes and a desc**tion of the quality of the evidence. Detailed evidence tables are included in appendix 10.9. The health economics evidence review, including a summary of a relevant Health Technology Assessment (HTA)1 report, is described in section 2.4.

    The evidence to recommendations section (section 2.5) captures all of the discussion by the Guideline Development Group (GDG) about the quality of the evidence, and outlines how the GDG reached decisions, based on the evidence or on consensus, to make specific recommendations.
  點(diǎn)擊下載完整版地址：《神經(jīng)性疼痛藥物治療指南》